Merck KGaA's Cladribine Revival Smacks Of Desperation
This article was originally published in Scrip
In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.
Register for our free email digests: